Wire · operational-macro
Analysts 'extremely bullish' as Telix beams into Novartis' territory with $1.6B ITM acquisition
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Telix Pharmaceuticals is acquiring ITM Isotope Technologies Munich for $1.65 billion upfront, aiming to expand its radiopharmaceutical pipeline and manufacturing network, especially targeting competition with Novartis in radioligand therapies. The deal includes milestone payments linked to FDA approvals and sales targets of ITM-11, a key therapy that previously faced manufacturing issues with the FDA but is expected to be resubmitted for approval.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 21 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
Telix is consolidating its position in radiopharmaceuticals by acquiring ITM’s R&D and manufacturing assets, opening a path to challenge Novartis’ dominance. You need to reconsider your market positioning now as this will intensify competition and shift supply relationships in this niche.
◆ Coverage
4 sources · first reported 21 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics